title: An ECLIPSE View of Alpha-1 Antitrypsin Deficiency.
abstract: Chronic obstructive pulmonary disease (COPD) is a multicomponent condition that is estimated to become the third leading cause of death in 2020. The ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, funded by GlaxoSmithKline, is an observational study designed to define outcomes that can be used as endpoints in clinical trials in individuals with COPD. It allowed us to describe the heterogeneity of COPD, the stability of the exacerbation phenotype, and the factors associated with a progressive decline in lung function and the progression of emphysema on computed tomography scans. The cohort was also used to define genetic factors and biomarkers associated with COPD and disease progression. This review considers how the results from ECLIPSE can inform our understanding of the lung disease associated with alpha-1 antitrypsin deficiency.
authors: Wolfson Institute for Biomedical Research, Division of Medicine, University College London, United Kingdom.
authors: David A
authors: DA
authors: Lomas
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D018450:Disease Progression; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*; D011656:Pulmonary Emphysema / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D014057:Tomography, X-Ray Computed; D019896:alpha 1-Antitrypsin Deficiency / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology*
chemical_list: D015415:Biomarkers
keywords: Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study; antitrypsin; chronic obstructive pulmonary disease